Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients
Public ClinicalTrials.gov record NCT07646613. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled, Crossover, Multi-center Clinical Trial for the Evaluation of Efficacy, Safety, and Tolerability of ASY202 for the Acute Treatment of Migraine in Adult Patients
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is testing an investigational inhaled migraine medication to see how well it works, how safe it is, and how well people tolerate it. Adults with migraine will receive both the study medication (ASY202) and a placebo (inactive treatment) at different times during the study. Neither participants nor study staff will know which treatment is given at the time. The medication is taken using a handheld dry powder inhaler to treat migraine attacks when they occur. Following screening, eligible participants will be enrolled and randomized to one of two treatments sequences i.e. one treatment sequence will receive ASY202 in treatment period 1 followed by placebo in treatment period 2 and other treatment sequence will receive placebo in treatment period 1 followed by ASY202 in treatment period 2. The study lasts about 16 weeks and includes a screening period, two treatment periods (with a minimum of 7 days washout period between the treatment periods), and a safety follow-up visit.
Study identification
- NCT ID
- NCT07646613
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 108 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 19, 2026 (Actual)
- Primary completion
- Mar 2027 (Estimated)
- Completion
- Mar 2027 (Estimated)
- Last update posted
- Oct 9, 2026
2026 – 2027
United States locations
- U.S. sites
- 20
- U.S. states
- 14
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Research Center | Phoenix | Arizona | 85053 | Recruiting |
| Synergy San Diego | Lemon Grove | California | 91945 | Recruiting |
| Sunwise Clinical Research, Llc | Walnut Creek | California | 94596 | Recruiting |
| New England Institute for Clinical Research | Stamford | Connecticut | 06905 | Recruiting |
| Chase Medical Research | Waterbury | Connecticut | 06708 | Recruiting |
| Clinical Neuroscineces Solutions - Orlando | Orlando | Florida | 32801 | Recruiting |
| Clinical Neuroscineces Solutions | Orlando | Florida | 32806 | Recruiting |
| Conquest Research | Atlanta | Georgia | 30328 | Recruiting |
| Boston Clinical Trials | Roslindale | Massachusetts | 02131 | Recruiting |
| Mass. Institute of Clinical Research | Westborough | Massachusetts | 01581 | Recruiting |
| StudyMetrix Research | City of Saint Peters | Missouri | 63303 | Recruiting |
| M3 Wake Research - Las Vegas Rainbow | Las Vegas | Nevada | 89118 | Recruiting |
| CenExel Marlton NJ | Marlton | New Jersey | 08053 | Recruiting |
| SPRI Clinical Trials | Brooklyn | New York | 11235 | Recruiting |
| M3 Wake Research | Raleigh | North Carolina | 27612 | Recruiting |
| CNS Healthcare | Memphis | Tennessee | 38119 | Recruiting |
| Clinical Research Associates, Inc. | Nashville | Tennessee | 37203 | Recruiting |
| FutureSearch Trials of Neurology | Austin | Texas | 78731 | Recruiting |
| FutureSearch Trials of Dallas | Dallas | Texas | 75251 | Recruiting |
| Highland Clinical Research | Salt Lake City | Utah | 84124 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07646613, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 9, 2026 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07646613 live on ClinicalTrials.gov.